Oppenheimer’s Colin Rusch angles for “intrigue,” but recognizes challenges still face TSLA.
Jason Kolbert recently downgraded MNKD on cash flow concerns; after this Q3 print, looks like he was right.
Snap misses across the board for Q3 earnings, stock gets whacked; Brian Wieser reiterates a Sell.
Is Valeant on track to overcome financial troubles? Mizuho’s Irina Rivkind Koffler remains unconvinced.
Oppenheimer predicts TXMD to launch TX-004HR by mid-2018 with a January approval from the FDA.
Rick Schafer: Data center and gaming momentum will bode well for NVDA’s anticipated quarterly outclass.
TX-004 is on the path to FDA approval; Cantor’s William Tanner Sees 450% Upside.
Dave Kang: OCLR shares wait on China to strengthen in the back half of F2018 and cloud recovery in F4Q .
Oppenheimer: The capture market is looking better and GPRO just made a strong comeback with 3Q results.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced the presentation of data from the Phase II -019 Study …